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Ischemia-hyperpnea test is useful to detect patients 
with fibromyalgia syndrome 
Abstract
Objective: To demonstrate the prevalence of neuromuscular hyperexcitability in Fibromyalgia Syndrome (FMS) by electromyography 
ischaemia-hyperpnea test (IHT) and its correlation with clinical and clinimetric parameters. 
Material and Methods: One hundred and forty-five FMS patients underwent IHT to evaluate neuromuscular hyperexcitability and were 
evaluated for pain (numeric Rating Scale and Regional Pain Scale), tenderness (tender points), disability [Fibromyalgia Impact Question-
naire (FIQ), Health Assessment Questionnaire (HAQ)], quality of life (QOL) [Short Form 36 (SF36)], mood [Hospital Anxiety and Depression 
Scale (HADS)], sleep [numeric rating scale (NRS)], and fatigue [Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)]. 
Results: Of the 145 patients, 95 were tested positive by IHT, and 33 and 17 patients were negative and borderline, respectively.
By comparing the three groups, IHT positive patients had lower age and lower SF36 vitality (V), social activities (SA), and mental summary 
index (MSI) than negative patients (p<0.05). 
By comparing positive versus negative patients and by comparing positive and borderline patients versus negative patients, it was found 
that FACIT was higher, whereas age, SF36 V, SA, mental health (MH), and MSI were lower (p<0.05). 
Conclusion: FMS patients present a high prevalence of neuromuscular hyperexcitability, as assessed by IHT. IHT positive patients have 
poor QOL and higher fatigue than IHT negative patients. Thus, IHT positivity could identify FMS patients with a more severe disease.  
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Introduction
Fibromyalgia syndrome (FMS) (1) is characterized by chronic widespread pain and focal tenderness sites 
(tender points) (2) associated with fatigue, stiffness, non-restorative sleep, irritable bowel, headache, rest-
less legs, depression, and cognitive symptoms (3). FMS impairs quality of life (QOL) (4), sociality (5), working 
activities (6), and mood (7). 
Because of a wide array of symptoms and the absence of specific tests confirming diagnosis, FMS is diag-
nosed by anamnesis and clinical examination, often years after the onset of symptoms (8). Thus, biochem-
ical and instrumental tools that aid in diagnosis are required (9).
FMS may be included in central sensitivity syndromes (10), in which sensory perception changes in the cen-
tral nervous system lead to pain exacerbation (11). In FMS, peripheral nociceptive inputs may also initiate 
and maintain central sensitization, thereby causing disordered central pain processing and dysfunctional 
pain (12, 13).
Unspecific bioptic abnormalities indicate that muscles may be involved in FMS pathogenesis (14). Mus-
cle abnormalities may contribute to sensitization of muscle nociceptors causing pain, fatigue, and muscle 
weakness and may favor peripheral sensitization of afferent pain pathways, thereby providing tonic im-
pulse input to central pathways, resulting in central sensitization (14). 
Because musculoskeletal pain is a cardinal symptom of FMS, electromyography (EMG) was used to evaluate 
muscular physiopathology and demonstrate changes both in involved (15) and uninvolved skeletal mus-
cles (16) in FMS with respect to controls.
EMG and, in particular, ischaemia-hyperpnea test (IHT), may detect neuromuscular hyperexcitability (NMH) 
(17, 18), which is defined as a reduction in the excitability threshold, that may be nonspecific or related to 
tetany. 
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Only two studies analyzed NMH in FMS by IHT. 
Vitali et al. (19) demonstrated a higher preva-
lence of NMH, assessed after the ischemia test, 
in FMS than in rheumatoid arthritis. Bazzichi et 
al. (20) reported 25.8% of a comorbid spasmo-
philia in FMS patients also presenting a higher 
incidence of depressive and panic disorders, 
as assessed by DSM-IV, and a lower number of 
tender points than FMS patients with no spas-
mophilia. 
The definition of spasmophilia is not univocal 
and its nosological identity is rather undefined. 
Gerson and Torunska defined spasmophilia as 
a latent tetany that is generally due to hypo-
magnesaemia or hyperventilation and not due 
to hypocalcemia (21, 22).
Vitali et al. (19), according to Munera et al. (23) 
considered NMH synonymous to normocalce-
mic tetany and spasmophilia and defined it as 
a condition characterized by motor, sensory 
(cramps, fasciculations, paresthaesias, rarely 
tetanic seizures), psychological, and visceral 
disturbances (19). Bazzichi et al (20) diagnosed 
spasmophilia based on clinical symptoms 
(which showed at least 1/4th of the following: 
cramps and/or tetanic seizures, paresthesia, 
tachycardia and/or dyspnea, asthenia, and diz-
ziness) and on the positive results of IHT. 
Thus, based only on IHT results, we chose to 
use the term NMH rather than spasmophilia.
Our principal aim is to demonstrate, the preva-
lence of NMH in FMS patients detected by IHT 
and to verify its potential utility as a diagnostic 
tool. 
Our secondary aim is to evaluate the correla-
tion of NMH, shown by IHT, with clinical and 
clinimetric parameters and to assess if FMS 
patients tested positive by IHT could have dif-
ferent characteristics with respect to patients 
tested negative. 
Material and Methods 
One hundred and forty-five FMS patients (134 
women and 11 men) were recruited from the 
outpatient clinic of the Division of Rheuma-
tology, Department of Experimental and Clin-
ical Medicine, University of Florence, Azienda 
Ospedaliera Universitaria (AOU) Careggi.
The inclusion criterion was the diagnosis of 
FMS according to the American College of 
Rheumatology (ACR) criteria (2).
The exclusion criteria were changes in thy-
roid function [Free triiodothyronine (FT3), 
free thyroxine (FT4), Thyroid-stimulating hor-
mone (TSH), Thyroperoxidase antibodies (ab) 
(TPOAb), thyroglobulin ab (TgAb), and TSHAb 
receptor Ab (TRAb)], electrolytes [(magnesium 
(Mg) and potassium (K)], and calcium (Ca) me-
tabolism including Ca, Parathyroid hormone 
(PTH), and 25-hydroxyvitamin D3 (25-OH vita-
min D3). 
All patients signed an informed consent 
form, and procedures were conducted in ac-
cordance with the Declaration of Helsinki of 
1975/83. The study was approved by our local 
ethics committee. 
Patients were evaluated for demographic char-
acteristic (age, sex), disease and symptoms du-
ration, diagnosis latency, treatments, presence 
of headache, neurogenic hypotension, irritable 
bowel syndrome, irritable bladder, restless legs 
syndrome, thyroid function electrolytes, and 
calcium metabolism. 
All patients were tested by standard EMG and 
nerve conduction studies (NCS) to rule out 
neuromuscular affections and with IHT to eval-
uate NMH (17, 24). 
Patients were also assessed for pain, tender-
ness, disability, sleep, fatigue, QOL, anxiety, and 
depression by clinic and clinimetric tools. 
Electromyography (EMG), nerve conduction 
studies (NCS), and ischaemia-hyperpnea test
EMG assesses the electrical potential formed 
in a muscle during its contraction [motor unit 
action potential (MUAP)], which reflects the ac-
tivity of a group of motor units. 
EMG/NCS and IHT were performed with a 
Synergy electromyography equipment (VI-
ASYS HealthCare UK, Manor Way, Old Woking, 
Surrey, GU22 9JU, UK., 2007) by using surface 
electrodes for NCS and coaxial needles for EMG 
and IHT. 
For IHT, a coaxial needle was inserted in the 
1st dorsal interosseous dorsal muscle of the 
left hand. The examination consisted of two 
phases:
1. Ischaemia phase: (5 min) Caused by ap-
plying the cuff of the sphyngomanome-
ter (blood pressure cuff) to the lower third 
of the arm with a pressure of 200 mgHg. 
2. Hyperpnea phase: (3 min) Immediately 
after ischaemia, executed by inviting the 
patient to perform a deep hyperven-
tilation, with a frequency of around 40 
breaths/ min. 
In normal subjects, no spontaneous activity is 
present in the muscle at rest and during IHT. A 
singlet is a spontaneous involuntary discharge 
of an individual motor unit. Spontaneous 
MUAPs firing in groups of two, three, or multi-
ple potentials are defined as doublets, triplets, 
and multiplets. These potentials and the sin-
glets represent the spontaneous depolariza-
tion of a motor unit or its axon. 
The carpal spasm (tetany), which can be ob-
served during the ischaemia phase, is not sup-
ported by multiplets but by EMG activity (sub-
interferential pattern), similar to that observed 
during voluntary recruitment. When doublets, 
triplets, and multiplets are not associated with 
carpal spasms or tetany, the condition is de-
fined as non-specific NMH. 
In our study, FMS patients were divided into 
three groups according to IHT results: positive: 
when doublets, triplets, or multiplets were 
present during hyperpnea (25); borderline: if 
some fasciculations and/or single doublets 
were present during hyperpnea; and negative: 
if spontaneous activity was absent (17).
Clinimetric assessment
Pain was rated with the numeric rating scale 
(NRS) (0-10, 0=no pain, 10=severe pain) and 
the regional pain scale (RPS) (score: 0-19) (26).
Tenderness was evaluated with the digital pal-
pation of 18 tender points recognized by ACR as 
a criterion for FMS classification (score: 0-18) (2). 
Disability was rated by the Italian versions of 
the Fibromyalgia Impact Questionnaire (FIQ) 
(score 0-100) (27, 28) and the Health Assess-
ment Questionnaire (HAQ) (score 0-3) (29). 
QOL was assessed by the Medical Outcomes 
Survey Short Form 36 (MOS-SF36) (30), orga-
nized into eight domains measuring physical 
functioning (PF), role limitations due to phys-
ical problems (PP), bodily pain (BP), general 
health perceptions (GH), vitality (V), social 
functioning (SF), role limitations due to emo-
tional problems (EP), and mental health (MH), 
combined into the summary physical index 
(SPI) and the summary mental index (SMI); for 
all scales score is 0-100.
Psychological distress was assessed by the 
Hospital Anxiety and Depression Scale (HADS), 
with subscales for anxiety (HADS-a) and de-
pression (HADS-d). For both the subscales, the 
scores range from 0 (no depression or anxiety) 
to 21 (maximal depression or anxiety) (31).
Quality of sleep was rated by NRS 0-10, with 
0=the worst perceived sleep and 10=the best 
perceived sleep.
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Fatigue was assessed by the Functional Assess-
ment of Chronic Illness Therapy-Fatigue scale 
(FACIT-F) (32) (range 0-52).
Statistical analysis 
Continuous and binomial variables are present-
ed as mean±standard deviation and as numbers 
and percentages. The Kolmogorov-Smirnov test 
was used to verify the probability distribution of 
the samples. To compare for clinical characteris-
tics of groups, Fischer’s exact test or χ2 test were 
used to test for binomial variables, and unpaired 
t-test and analysis of variance (ANOVA) were 
used to compare continuous variables in two or 
three groups. 
The significance was set at a p-value<0.05. All 
analyses were performed using SPSS version 
20.0 for Windows (SPSS, Chicago, IL, US).
Results 
Demographic, clinical, and pharmacological 
characteristics of FMS patients according to 
results of IHT 
No patient showed alterations in NCS and in 
EMG. According to the results of IHT, 145 FMS 
patients were divided in three groups: positive 
[95 patients (62.52%)]; negative [33 patients 
(22.76%)]; and borderline [17 pts (11.72%)]. 
Demographic and clinical characteristics and 
treatments are shown in Table 1. 
In all FMS patients, all the parameters of thyroid 
function, calcium metabolism, and blood elec-
trolytes were normal. 
Age was higher in positive versus negative pa-
tients (p<0.05). The patients of the three groups 
reported a different distribution for irritable 
bladder disease and for the use of non-steroi-
dal anti-inflammatory drugs (NSAIDs) and anal-
gesics (p=0.03 in both cases). 
Comparison of clinical and clinimetric 
characteristics of FMS patients divided in three 
groups (positive, negative, and borderline) 
according to IHT 
As shown in Table 2, comparison of the three 
groups of FMS patients revealed the following 
results: age (p<0.05), SF36 V (p=0.0155), SF36 
SF (p=0.0062), and SF36 MSI scores (p=0.0113) 
were significantly lower in positive versus neg-
ative patients. 
No significant differences were found between 
positive versus borderline patients and be-
tween negative versus borderline patients. 
Comparison of clinical and clinimetric 
characteristics of FMS patients: 
positive versus negative according to IHT
In positive versus negative patients, FACIT 
was higher (p=0.038) and age (p=0.01), SF36 
V (p=0.005), SF36 SF (p=0.002), SF36 MH 
(p=0.039), and SF36 MSI (p=0.004) were lower 
(Table 3). 
Comparison of clinical and clinimetric 
characteristics of FMS patients: positive and 
borderline versus negative according to IHT
On comparing positive and borderline patients 
with negative patients, the IHT findings were 
similar with respect to the comparison of FMS 
positive versus negative patients. 
In positive and borderline versus negative pa-
tients, FACIT was higher (p=0.048) and age 
(p=0.02), SF36 V (p=0.007), SF36 SF (p=0.002), 
SF36 MH (p=0.036), and SF36 SMI (p=0.003) 
were lower (Table 4).
Discussion
In our study, the results of IHT were positive in 
>60% of FMS subjects, indicating the presence 
of NMH in the majority of patients. 
Because all subjects demonstrated normal 
calcium metabolism, independent from test 
results (positive, borderline, or negative), NMH 
was not linked to hypocalcemia and/or hypo-
parathyroidism. Moreover, demographical and 
clinical characteristics were homogeneous 
among groups because only age was higher in 
positive versus negative patients.
Our results are different from those shown by 
Bazzichi et al. (20); we diagnosed spasmophilia 
in 25.80% of FMS patients. This difference is ob-
served because we have assessed NMH only by 
IHT, whereas Bazzichi et al (20). diagnosed spas-
mophilia as a comorbid and distinct condition 
of FMS, based on both clinical and EMG criteria. 
Vitali et al (19) found at least two clinical features 
of spasmophilia in 39% of FMS patients and a 
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Table 1. Demographic, clinical, and pharmacological characteristics of FMS patients according 
to results of IHT  
 Positive  Negative Borderline 
 (95 patients) (33 patients)  (17 patients)  p
Females 87/95 (91.59%) 31/33 (93.94%) 16/17 (94.12%) NS 
Age (years) 52.55±12.10  58.76±10.62  55.82±15.67  <0.05  
    (positive vs  
    negative)
Disease duration  8.18±9.30 10.53±12.24 6.06±5.51 NS
Latency of diagnosis 6.52±7.00 6.66±10.33 5.06±5.69 NS
Irritable bowel 59/95 (62.11%) 20/33 (60.61%) 11/17 (64.71%) NS 
Irritable bladder 40/95 (42.10%) 9/33 (27.27%) 2/17 (11.76%) 0.03 
Cephalalgia 69/95 (72.63%) 21/33 (63.64%) 9/17 (52.94%) NS 
Restless leg syndrome  68/95 (71.58%) 24/33 (72.73%) 12/17 (70.59%) NS 
Neurogenic hypotension  29/95 (30.53%) 7/33 (21.21%) 7/17 (41.18%) NS 
NSAIDS  47/95 (49.47%) 23/33 (69.70%) 7/17 (41.18%) 0.03
Glucocorticoids  9/95 (9.47%) 6/33 (18.18%) 1/17 (5.88%) NS 
Antidepressant 33/95 (34.74%) 12/33 (36.36%) 7/17 (41.17%) NS 
Anxiolytic benzodiazepines 24/95 (25.26%) 5/33 (15.15%) 2/17 (11.76%) NS 
Hypnotic benzodiazepines 12/95 (12.63%) 4/33 (12.12%) 3/17 (17.65%) NS 
Pregabalin 6/95 (6.32%) 1/33 (3.03%) 1/17 (5.88%) NS 
Gabapentin  5/95 (5.26%) 0/33 (0.00%) 0/17 (0.00%) NS 
Phytotherapy 12/95 (12.63%) 5/33 (15.15%) 0/17 (0.00%) NS 
Homeopathy 6/95 (6.32%) 2/33 (6.06%) 0/17 (0.00%) NS 
Continuous data are presented as mean±SD; binomial data are presented as numbers and percentages; NSAIDs: non-steroidal 
anti-inflammatory drugs
post-ischemic spontaneous EMG hyperactivity 
in 22.45% of FMS patients (19). In our opinion, 
symptoms such as paresthesia, muscle stiffness 
and contractures, cramps, tachycardia, dyspnea, 
asthenia, and dizziness, other than anxious and 
panic crisis and restless legs syndrome, could be 
part of the wide array of FMS manifestations (2) 
rather than being representative of spasmophilia. 
It should also be noted that IHT is not standard-
ized; therefore, the procedures and the devices 
may be different according to the studies, and 
the results may not be easily comparable. 
Bazzichi et al. (20) used surface electromyogra-
phy (SEMG) and defined IHT positivity in the pres-
ence of doublets, triplets, and multiplets after the 
application of 10 min of ischaemic stimulus (pres-
sure >20 mmHg of the patient’s systolic blood 
pressure, by a blood pressure cuff of a sphyngo-
manometer) or during 3 min of hyperpnea. 
Vitali et al. (19) also used SEMG and applied 
only ischaemia stimulus (pressure of 20-30 
mmHg above systolic blood pressure) and 
defined IHT positivity in the presence of multi-
plets during a 3.30-4 min post-ischemic period 
of monitoring.
Conversely, we used coaxial needles, and IHT was 
considered positive at the onset of spontaneous 
motor activity (indicated as doublets, triplets, 
and multiplets) during the ischaemia and hyper-
pnea phase. In our case, ischaemia was induced 
by applying a pressure of 200 mgHg by the cuff 
of the sphyngomanometer for 5 min (17, 24). 
We know that hyperventilation determines 
respiratory alkalosis with an increase in arterial 
pH, leading to a decrease in the free ionized Ca 
level in the plasma (18, 20) and that hypocal-
caemia alone can induce paraesthesiae and 
may determine spontaneous activity such as 
fasciculation and/or poliplets by modifying 
membrane excitability. 
We can hypothesize that the onset of fascicu-
lation or/and poliplets in FMS patients relies on 
the different excitability of muscle membrane 
(33) and/or axon membrane (18) shown in FMS 
with respect to controls, which leads to NMH. 
In agreement with the literature, all our FMS 
patients demonstrated impaired QOL, disability, 
and fatigue (4-6, 34). Clinimetric results were dif-
ferently impaired by stratifying patients accord-
ing to the results of IHT. By comparing positive 
with negative and borderline patients, patients 
tested positive by IHT had poor scores in vitali-
ty, social functioning, and in overall mental QOL 
than patients tested negative by IHT. 
By comparing only positive versus negative 
patients, these results were confirmed and 
also differences in fatigue and mental health 
(worse in positive than in negative patients) 
were shown.
NMH, as defined by positivity at IHT, is present 
in majority of our FMS patients and identifies 
patients in which fibromyalgic symptoms cause 
a higher distress, leading to QOL impairment. 
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 Positive  Negative  Borderline  ANOVA overall effect  p vs. n p vs. B  n vs. B 
HADS-A 10.80±4.47 9.70±3.90 10.19±4.18 NS NS NS NS
HADS-D  9.10± 4.86 8.58±4.58 9.25±3.59 NS NS NS NS
HADS-TOT 19.88±8.74 18.27±7.74 19.44±7.15 NS NS NS NS
Sleep quality  4.35±2.42 4.62±2.26 4.82±2.43 NS NS NS NS
Pain  5.86±2.53 5.67±2.55 6.24±3.08 NS NS NS NS
Tender points  15.63±3.85  14.74±4.18 15.72±3.41 NS NS NS NS
FIQ 54.49±19.03 49.01±20.72 54.45±22.56 NS NS NS NS
HAQ 1.13±1.41 0.85±0.57 2.15±5.41 NS NS NS NS
FACIT  24.61±10.83 20.06±9.64 22.29±10.01 NS NS NS NS
SF36 PF 49.83±22.87 54.85±23.93 52.50±25.82 NS NS NS NS
SF 36 PP 21.51±31.66 34.85±40.96 31.25±38.19 NS NS NS NS
SF36 BP 30.83±16.59 37.45±20.76 33.35±24.98 NS NS NS NS
SF36 GH 35.77±21.84 37.15±20.24 35.31±18.35 NS NS NS NS
SF36 vitality 30.29±20.41 42.33±21.60 36.25±16.68 0.0155 <0.05 NS NS
SF36 SF 44.34±23.16 60.36±28.27 49.81±18.69 0.0062 <0.05 NS NS
SF 36 EP 33.10±38.13 45.88±40.93 26.88±32.52 NS NS NS NS
SF36 MH 46.4±20.86 55.18±19.85 48.75±13.24 NS NS NS NS
SF36 SPI 32.22±8.37 34.03±10.15 33.81±11.34 NS NS NS NS
SF36 SMI 34.01±11.27 40.94±11.62 35.00±7.83 0.0113 <0.05 NS NS
RPS 13.58±4.30 12.03±5.22 13.29±5.59 NS NS NS NS
Tender points  15.63±3.85 14.74±4.18 15.57±4.02 NS NS NS NS
Continuous data are presented as mean±SD; HADS: hospital anxiety and depression scale; HADS-a: HADS subscale for anxiety; HADS-d: HADS subscale for depression; FIQ: fibromyalgia impact 
questionnaire; HAQ: health assessment questionnaire; FACIT: functional assessment of chronic illness scale; SF36: short form 36; SF36 PF: physical functioning; SF36 PP: role limitations due to 
physical problems; SF36 BP: bodily pain; SF36 GH: general health perceptions; SF36 V: vitality (V); SF36 SF: social functioning; SF36 EP: role limitations due to emotional problems; SF36 MH; mental 
health (MH); SF36 SPI: summary physical index; SF36 SMI: summary mental index; RPS: regional pain scale
Table 2. Clinical and clinimetric characteristics of FMS patients divided in three groups (positive, negative, and borderline) according to IHT 
Fatigue, both due to and causing disability, is 
one of the cardinal features of FMS. It is related 
both to tiredness (of central origin) and to pe-
ripheral muscle fatigue (34). Our FMS patients 
with NMH presented major fatigue at FACIT and 
lower vitality scores at SF 36 (meaning high fa-
tigue) than patients tested negative by IHT. 
Concordantly with previous data (20), no differ-
ences in FMS groups according to IHT results 
were found in disability. 
Bazzichi et al. (20) found patients with spasmo-
philia and FMS as having higher tender point 
counts than subjects with FMS alone. In our 
study, referred pain and tenderness were not 
different according to test results. This confirms 
that IHT positivity is more related to general dis-
tress than to peripheral pain and tenderness.
We showed that anxious and depressive symp-
toms, evaluated by HADS, were not different 
according to the test results. This is concordant 
with Bazzichi et al. (20), who found a similar 
percent of anxiety and depression as self-re-
ported symptoms in both groups. However, 
in this study, when FMS patients were admin-
istered with the structured clinical interview 
for Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition (DSM-IV), those tested 
negative by IHT were significantly more affect-
ed by psychiatric comorbidities (indicated by 
depression and panic disorders) than positive 
patients (20). The authors explain this discrep-
ancy as due to a distortion of mood perception 
present in both groups of patients. 
The diagnosis of FMS is still difficult, under-es-
timated, and often delayed (8); therefore, tests 
that are able to confirm or facilitate the diagno-
sis are required (9).
Based on bioptic, metabolic, and molecular 
studies, muscles are retained as involved in FMS 
diagnosis (14). Sensitization of muscle nocicep-
tors may cause pain, fatigue, and muscle weak-
ness and results in peripheral sensitization of 
afferent pain pathways, thereby providing tonic 
impulse input to central pathways and leading 
ultimately to central sensitization (14).
EMG, used in different studies to evaluate 
muscular physiopathology in FMS, revealed al-
tered muscle fiber conduction velocity (CV) in 
involved muscles (15) and high muscle mem-
brane CV in muscles not involved in FMS (33), 
suggesting an overall muscular membrane 
disorder and electrical manifestation of muscle 
fatigue (16, 34).
IHT may detect NMH, defined as a reduction in 
the threshold of excitability of skeletal muscles 
(17, 18). From our results, we may hypothesize 
that NMH is common in patients with FMS and 
IHT could be helpful in diagnosing FMS. 
We may also infer IHT positivity helps to identi-
fy FMS patients with lower QOL, higher fatigue, 
higher distress, and disease severity. IHT positiv-
ity may also be useful in better tailoring treat-
ment interventions, particularly non pharmaco-
logical treatments such as mind body therapies, 
dealing efficaciously with disability, psychologi-
cal distress, fatigue, and exercises (35).
Limitations of our study can be the absence of 
a control group; however, this group is neither 
present in previous studies assessing IHT in 
FMS (19, 20) nor in its transversal design. Future 
studies on wider cohorts of patients and with 
longitudinal design are required to confirm the 
efficacy of IHT in FMS, its eventual change over 
time, and its relationship with psychological, 
physical, and disease-associated problems. 
In conclusion, >60% of our FMS patients have 
IHT positivity, indicating a high prevalence of 
NMH. 
Patients positive to the test have poor QOL and 
higher fatigue than those negative to the test. 
Thus, we may also infer that IHT positivity could 
help diagnose FMS and identify patients with a 
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Table 3. Clinical and clinimetric characteristics of FMS patients: positive versus negative 
according to IHT
 Positive  Negative  p 
Age  52.55±12.10 58.76±10.62 0.0101
Disease duration  8.18±9.30 10.53±12.24 NS
Latency  6.52±7.0 6.66±10.33 NS
HADS-A 10.80±4.47 9.70±3.90 NS
HADS-D  9.10±4.86 8.58±4.58 NS
HADS-TOT 19.88± 8.74 18.27±7.74 NS
Sleep quality  4.35±2.42 4.62±2.26 NS
Pain  5.86±2.53 5.67±2.55 NS
FIQ 54.49±19.03 49.01±20.72 NS
HAQ 1.13±1.41 0.85±0.57 NS
FACIT  24.61±10.83 20.06±9.64 0.0377
SF36 PF 49.83±22.87 54.85±23.93 NS
SF 36  PP 21.51±31.66 34.85±40.96 NS
SF36  BP 30.83±16.59 37.45±20.76 NS
SF36 GH 35.77±21.84 37.15±20.24 NS
SF36 V 30.29±20.41 42.33±21.60 0.0054
SF36  SF 44.34±23.16 60.36±28.27 0.002
SF 36 EP 33.10±38.13 45.88±40.93 NS
SF36 MH 46.40±20.86 55.18±19.85 0.039
SF36 SPI 32,22±8.37 34.03±10.15 NS
SF36 SMI 34.01±11.27 40.94±11.62 0.004
RPS 13.58±4.30 12.03±5.22 NS
Tender points  15.63±3.85 14.74±4.18 NS
Continuous data are presented as mean ± DS; HADS: hospital anxiety and depression scale;  HADS-a: HADS subscale for anxiety; 
HADS-d: HADS subscale for depression; FIQ: fibromyalgia impact questionnaire; HAQ: health assessment questionnaire; FACIT: 
functional assessment of chronic illness scale; SF36: short form 36;  SF36 PF: physical functioning; SF36 PP: role limitations due 
to physical problems; SF36 BP: bodily pain; SF36 GH: general health perceptions; SF36 V: vitality (V); SF36 SF: social functioning; 
SF36 EP:  role limitations due to emotional problems; SF36 MH; mental health (MH); SF36 SPI: summary physical index;  SF36 SMI: 
summary mental index; RPS: regional pain scale
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more severe disease and may also be useful in 
better tailoring treatments. 
Ethics Committee Approval: Ethic committee approval was 
received for this study from our Local Ethical Committee.
Informed Consent: Written informed consent was ob-
tained from patients who participated in this study.
Peer-review: Externally peer-reviewed.
Author Contributions: Concept - S.M.B., A.D.R.; Design 
- S.M.B., A.D.R.; Supervision - G.D.S.; Materials - D.L., 
M.O.; Data Collection and/or Processing - A.D.R., D.L., 
M.O.; Analysis and/or Interpretation - S.M.B., A.D.R, 
D.L., M.O., G.D.S.; Literature Review - D.L., M.O.; Writers 
- A.D.R., D.L.; Critical Review - G.D.S., S.M.B.
Conflict of Interest: No conflict of interest was de-
clared by the authors.
Financial Disclosure: The authors declared that this 
study has received no financial support.
References
1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. 
The prevalence and characteristics of fibromy-
algia in the general population. Arthritis Rheum 
1995; 38:19-28. [CrossRef]
2 Wolfe F, Smithe HA, Yunus MA, Bennett RM, 
Bombardier C, Goldenberg DL et al. The Amer-
ican College of Rheumatology 1990 criteria 
for the classification of fibromyalgia”. Arthritis 
Rheum 1990; 33: 160-72. [CrossRef]
3. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg 
DL, Katz RS, Mease P et al. The American Col-
lege of Rheumatology preliminary diagnostic 
criteria for fibromyalgia and measurement of 
symptom severity. Arthritis Care Res (Hoboken) 
2010; 62: 600-10. [CrossRef]
4. Salaffi F, Sarzi-Puttini P, Girolimetti R, Atzeni F, 
Gasparini S, Grassi W. Health-related quality of 
life in fibromyalgia patients: a comparison with 
rheumatoid arthritis patients and the general 
population using the SF-36 health survey. Clin 
Exp Rheumatol 2009; 27(5 Suppl 56): 67-74.
5. Henriksson C, Gundmark I, Bengtsson A, Ek AC. 
Living with fibromyalgia. Consequences for ev-
eryday life. Clin J Pain 1992; 8: 138-44. [CrossRef]
6. Palstam A, Bjersing JL, Mannerkorpi K. Which 
aspects of health differ between working and 
nonworking women with fibromyalgia? A 
cross-sectional study of work status and health. 
BMC Public Health 2012; 12: 1076. [CrossRef]
7. Consoli G, Marazziti D, Ciapparelli A, Bazzichi L, 
Massimetti G, Giacomelli C, et al. The impact of 
mood, anxiety, and sleep disorders on fibromyal-
gia. Compr Psychiatry 2012; 53: 962-7. [CrossRef]
8. Choy E, Perrot S, Leon T, Kaplan J, Petersel D, 
Ginovker A, Kramer E. A patient survey of the 
impact of fibromyalgia and the journey to di-
agnosis. BMC Health Serv Res 2010; 10: 102. 
[CrossRef]
9. Bazzichi L, Rossi A, Giacomelli C, Bombardieri S. 
Exploring the abyss of fibromyalgia biomark-
ers. Clin Exp Rheumatol 2010; 28(6 Suppl 63): 
125-30.
10. Kindler LL, Bennett RM, Jones KD. Central sen-
sitivity syndromes: mounting pathophysiologic 
evidence to link fibromyalgia with other com-
mon chronic pain disorders. Pain Manag Nurs 
2011; 12: 15-24. [CrossRef]
11. Yunus MB. Central sensitivity syndromes: a new 
paradigm and group nosology for fibromyalgia 
and overlapping conditions, and the related 
issue of disease versus illness. Semin Arthritis 
Rheum 2008; 37: 339-52. [CrossRef]
12. Cook DB, Lange G, Ciccone DS, Liu WC, Steffen-
er J, Natelson BH. Functional imaging of pain in 
patients with primary fibromyalgia. J Rheuma-
tol 2004; 31: 364-78.
13. Costigan M, Scholz J, Woolf CJ. Neuropathic 
pain: a maladaptive response of the nervous 
system to damage. Annu Rev Neurosci 2009; 
32: 1-32 [CrossRef]
14. Staud R. Peripheral pain mechanisms in chronic 
widespread pain. Best Pract Res Clin Rheumatol 
2011; 25: 155-64. [CrossRef]
15. Gerdle B, Ostlund N, Grönlund C, Roeleveld K, 
Karlsson JS. Firing rate and conduction velocity 
of single motor units in the trapezius muscle in 
fibromyalgia patients and healthy controls. J Elec-
tromyogr Kinesiol 2008; 18: 707-16. [CrossRef]
16. Bazzichi L, Dini M, Rossi A, Corbianco S, De Feo 
F, Giacomelli C, Zirafa C, Ferrari C, Rossi B, Bom-
bardieri S. Muscle modifications in fibromyalgic 
patients revealed by surface electromyography 
(SEMG) analysis. BMC Musculoskelet Disord 
2009; 10: 36. [CrossRef]
17. Ronchi O, Lolli F, Lori S, Nuti Ranucci E, Grippo A. 
The ischaemia-hyperpnea test in the evaluation 
of neuronal hyperexcitability syndrome. Electro-
myogr Clin Neurophysiol 1994; 34: 289-94.
18. Mogyoros I, Kiernan MC, Burke D, Bostock H. Ex-
citability changes in human sensory and motor 
Table 4. Clinical and clinimetric characteristics of FMS patients: positive and borderline versus 
negative according to IHT
 Positive+Borderline Negative p
Age (years) 53.05±12.69 58.76±10.62 0.02 
Disease duration  7.86±8.84 10.53±12.24 NS
Latency  6.30±8.31 6.66±10.33 NS
HADS-A 10.78±4.42 9.70±3.90 NS
HADS-D  9.12±4.68 8.58±4.58 NS
HADS-TOT 19.82±8.50 18.27±7.74 NS
Sleep quality  4.43±2.42 4.62±2.26 NS
Pain  5.92±2.61 5.67±2.55 NS
FIQ 54.48 ±19.50 49.01±20.72 NS
HAQ 1.28±2.46 0.85±0.57 NS
FACIT  24.25±10.70 20.06±9.64 0.048
SF36 PF 50.25±23.24 54.85±23.93 NS
SF 36 PP 23.04±32.75 34.85±40.96 NS
SF36 BP 31.21±18.03 37.45±20.76 NS
SF36 GH 35.70±21.24 37.15±20.24 NS
SF36 V 31.23±19.92 42.33±21.60 0.007
SF36 SF SF 45.20±22.53 60,36±28,27 0.002
SF 36 EP 32.13±37.23 45.88±40.93 NS
SF36 MH 46.76±19.83 55.18±19.85 0.036
SF36 SPI 32.48±8.86 34.03±10.15 NS
SF36 SMI 34.17±10.77 40.94±11.62 0.003
RPS 13.53±4.50 12.03±5.22 NS
Tender points  15.60±3.63 14.74±4.18 NS
Continuous data are presented as mean±SD; HADS: hospital anxiety and depression Scale;  HADS-a: HADS subscale for anxiety; 
HADS-d: HADS subscale for depression; FIQ: fibromyalgia impact questionnaire; HAQ: health assessment questionnaire; FACIT: 
functional assessment of chronic illness scale; SF36: short form 36;  SF36 PF: physical functioning; SF36 PP: role limitations due 
to physical problems; SF36 BP: bodily pain; SF36 GH: general health perceptions; SF36 V: vitality (V); SF36 SF: social functioning; 
SF36 EP: role limitations due to emotional problems; SF36 MH; mental health (MH); SF36 SPI: summary physical index; SF36 SMI: 
summary mental index; RPS: regional pain scale
Maddali Bongi et al. Ischemia-hyperpnea test in Fibromyalgia Eur J Rheumatol 2015
axons during hyperventilation and ischaemia. 
Brain 1997; 120 (Pt 2): 317-25. [CrossRef]
19. Vitali C, Tavoni A, Rossi B, Bibolotti E, Giannini 
C, Puzzuoli L, et al. Evidence of neuromuscular 
hyperexcitability features in patients with pri-
mary fibromyalgia. Clin Exp Rheumatol 1989; 
7: 385-90.
20. Bazzichi L, Consensi A, Rossi A, Giacomelli C, De 
Feo F, Doveri M, et al. Spasmophilia comorbidity 
in fibromyalgia syndrome. Clin Exp Rheumatol 
2010; 28(suppl.63): 546-550.
21. Gerson M, Merceron RE, Courreges JP.La Spas-
mofilia. Médecine Actuelle 1979; 612: 57-59.
22. Torunska K. Tetany as a difficult diagnostic prob-
lem in the neurological outpatient department. 
Neurol Neurochir Pol 2003; 373: 653-64.
23. Munera Y, Hugues FC, Gillet J, Ely C, Marche J. 
Symptomatology in 162 patients with spasmo-
philia (chronic idiopathic or constitutional teta-
ny). A statistical analysis using a computer. Ann 
Med Interne (Paris) 1979; 130: 9-15.
24. Arnetoli G, Massi S, Canova S, Caramelli R, Ren-
zulli I, Fuzzi G, De Scisciolo G. Il test ischemia-ip-
erpnea e il dosaggio del Ca++ EMG++ in pa-
zienti con cefalea primaria (emicrania e cefalea 
tensiva). Abstract Book Congresso Nazionale 
della Società Italiana di Neurofisiologia Clinica, 
15-18 Maggio 1996, p. 156
25. Macefield G, Burke D. Paraesthesiae and tetany 
induced by voluntary hyperventilation. Brain 
1991; 114: 527-40. [CrossRef]
26. Wolfe F. Pain extent and diagnosis: develop-
ment and validation of the regional pain scale 
in 12,799 patients with rheumatic disease. J 
Rheumatol 2003; 30: 369-78.
27. Bennett R. The Fibromyalgia Impact Question-
naire (FIQ): a review of its development, current 
version, operating characteristics and uses. Clin 
Exp Rheumatol 2005; 23(5 Suppl 39): 154-62.
28. Sarzi-Puttini P, Atzeni F, Fiorini T, Panni B, Randi-
si G, Turiel M, et al. Validation of an Italian ver-
sion of the Fibromyalgia Impact Questionnaire 
(FIQ-I). Clin Exp Rheumatol 2003; 21: 459-64.
29. Ranza R, Marchesoni A, Calori G, Bianchi G, Bra-
ga M, Canazza S, et al. The Italian version of the 
Functional Disability Index of the Health As-
sessment Questionnaire. A reliable instrument 
for multicenter studies on rheumatoid arthritis. 
Clin Exp Rheumatol 1993; 11: 123-8.
30. Apolone G, Cifani S., Mosconi P. Questionario 
sullo stato di salute SF-36. Traduzione e validazi-
one della versione italiana: risultati del progetto 
IHRQoLA. Metodologia e Didattica Clinica 1997; 
5: 86-94.
31. Zigmond AS, Snaith PR. The Hospital Anxiety 
and Depression Scale. Acta Psichiatr Scand 
1983; 67: 361-370. [CrossRef]
32. Cella D, Yount S, Sorensen M, Chartash E, Sen-
gupta N, Grober J. Validation of the Functional 
Assessment of Chronic Illness Therapy Fatigue 
Scale relative to other instrumentation in pa-
tients with rheumatoid arthritis. J Rheumatol 
2005; 32: 811-9.
33. Klaver-Król EG, Zwarts MJ, Ten Klooster PM, 
Rasker JJ. Abnormal muscle membrane func-
tion in fibromyalgia patients and its relationship 
to the number of tender points. Clin Exp Rheu-
matol 2012; 30(6 Suppl 74): 44-50.
34. Casale R, Rainoldi A. Fatigue and fibromyalgia 
syndrome: clinical and neurophysiologic pat-
tern. Best Pract Res Clin Rheumatol 2011; 25: 
241-7. [CrossRef]
35. Maddali Bongi S, Del Rosso A. Mind Body Thera-
pies in the Rehabilitation Program of Fibromyal-
gia Syndrome. In Wilke WS, editor. New Insights 
into Fibromyalgia: InTech 2011. p 169-186. 
